CIK 0001668243
- Non-accelerated filer
- Smaller reporting company
UroGen Pharma Ltd.
Sign in to watch- Ticker
- URGN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- Operating
- Phone
- +972 97707601
- Business address
- 9 HA'TA'ASIYA ST, RA'ANANA, Israel, 4365007
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $182,793
- in 3 filings
Net −$182,793. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-04-26 | Schoenberg Mark Chief Medical Officer | Sale | −89 | $19.63 | $2K | 20,875 |
| 2021-04-26 | Schoenberg Mark Chief Medical Officer | Exercise or conversion · Restricted Stock Units | −209 | 625 | ||
| 2021-03-26 | Belldegrun Arie Director | Exercise or conversion | +3,241 | $5.00 | $16K | 245,452 |
| 2021-03-26 | Belldegrun Arie Director | Exercise or conversion · Stock Option (right to buy) | −3,241 | 0 | ||
| 2021-03-25 | Nussbaum Ran Director | Exercise or conversion | +1,030 | $5.00 | $5K | 1,431,717 |
| 2021-03-25 | Nussbaum Ran Director | Exercise or conversion · Stock Option (right to buy) | −1,030 | 0 | ||
| 2021-03-25 | Nussbaum Ran Director | Exercise or conversion | +2,211 | $5.00 | $11K | 1,433,928 |
| 2021-03-25 | Nussbaum Ran Director | Exercise or conversion · Stock Option (right to buy) | −2,211 | 0 | ||
| 2021-03-24 | Belldegrun Arie Director | Exercise or conversion | +3,241 | $5.00 | $16K | 245,452 |
| 2021-03-24 | Belldegrun Arie Director | Exercise or conversion · Stock Option (right to buy) | −3,241 | 0 | ||
| 2021-03-24 | Nussbaum Ran Director | Exercise or conversion | +1,030 | $5.00 | $5K | 1,465,199 |
| 2021-03-24 | Nussbaum Ran Director | Exercise or conversion · Stock Option (right to buy) | −1,030 | 0 | ||
| 2021-01-31 | Barrett Elizabeth A. Chief Executive Officer | Exercise or conversion | +5,000 | 242,924 | ||
| 2021-01-31 | Barrett Elizabeth A. Chief Executive Officer | Exercise or conversion · Restricted Stock Units | −5,000 | 10,000 | ||
| 2021-01-31 | Henderson Molly Chief Financial Officer | Grant or award · Stock Option (right to buy) | +6,000 | 6,000 | ||
| 2021-01-31 | Henderson Molly Chief Financial Officer | Grant or award · Restricted Stock Units | +2,000 | 2,000 | ||
| 2021-01-31 | Smith Jason Drew General Counsel | Grant or award · Stock Option (right to buy) | +8,000 | 8,000 | ||
| 2021-01-31 | Smith Jason Drew General Counsel | Grant or award · Restricted Stock Units | +2,500 | 2,500 | ||
| 2021-01-31 | Barrett Elizabeth A. Chief Executive Officer | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2021-01-31 | Barrett Elizabeth A. Chief Executive Officer | Grant or award · Restricted Stock Units | +40,000 | 40,000 |
Page 17 of 25 · 496 trades